This clinical trial examines whether using minimal residual disease (MRD) status, detected by circulating tumor DNA (ctDNA), can guide treatment after surgery for certain colon cancer patients. MRD is a small number of cancer cells that might remain after surgery. Adjuvant therapy is extra treatment given after the main treatment (like surgery) to help lower the risk of cancer coming back. The study focuses on high-risk stage II and low-risk stage III colon cancer patients.

• Participants will be divided into groups based on their MRD status after surgery and will have follow-ups for up to 5 years.
• Involves check-ups every 3 months for MRD detection and every 6 months for radiology tests.
• Participants must be between 18 and 70 years old, with no history of certain treatments or other cancers.

This study helps to understand if those without MRD need less treatment and if those with MRD need more intensive treatment. It's important for participants to commit to regular follow-ups and provide necessary samples for testing.